Focused On-demand Library for DNA repair protein RAD51 homolog 3

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our high-tech, dedicated method is applied to construct targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

O43502

UPID:

RA51C_HUMAN

Alternative names:

RAD51 homolog C; RAD51-like protein 2

Alternative UPACC:

O43502; O43503; Q3B783

Background:

DNA repair protein RAD51 homolog 3, also known as RAD51C, plays a pivotal role in the homologous recombination (HR) pathway of DNA repair, crucial for maintaining genomic stability. It is involved in the repair of double-stranded DNA breaks, a critical process for preventing mutations that could lead to cancer. RAD51C is part of the RAD51 paralog protein complexes BCDX2 and CX3, which facilitate different stages of the DNA repair process.

Therapeutic significance:

RAD51C is directly linked to diseases such as Fanconi anemia complementation group O and familial breast-ovarian cancer, highlighting its critical role in DNA repair mechanisms. Understanding the function of RAD51C could lead to breakthroughs in therapeutic strategies for these conditions, offering hope for patients with a genetic predisposition to cancer.